Automated Flow Cytometry Enables Standardized, Rapid Profiling of Cellular Starting Material for Predictable, Potent Products
This poster presents the ACCELLIX™ solution and how it provided better control of starting materials.
Summary
- Characterization of starting material is now seen as integral for ensuring downstream product quality.
- Cell therapy drug product potency is sensitive to the quality and composition of the starting material, including heterogeneity in cell subset frequencies and functional states, and sample handling conditions during collection and transportation.
- Understanding cellular attributes of this material allows manufacturers to establish appropriate potency metrics and predict functionality of the final product.
The ACCELLIX™ automated flow cytometry platform harmonizes results across operators and sites, providing a meaningful step forward in standardization of flow cytometry and linking starting material assessment with predictable, potent cell therapy products.
Download the Poster
Complete the form below to access the poster, which will be sent directly to your email after submission. By providing your information, you agree to receive additional emails from bioMérieux about cell therapy quality control.
To find out more about the management of your personal data and to exercise your rights, see our privacy policy.
